Renal Dysfunction, Metabolic Syndrome and Cardiovascular Disease Mortality

Table 2

Distribution of Independent Variables and Cardiovascular Disease Mortality (𝑛=13115).

Independent variables	No CVD mortality	CVD mortality
	frequency (%)	frequency (%)
Percentage of population	88.2%	11.8
Race
White	84.5%	15.5%
African american	90.7%	9.3%
Hispanic & other	92.9%	7.1
Gender
Male	87.1%	12.9%
Female	89.1%	10.9
Age (years)
<64	97.2%	2.8%
≥65	74.7%	25.3
Poverty/income ratio
<1	84.9%	15.1%
≥1	90.0%	10.0
Smoking status
Never smoked	88.0%	12.0%
Ever-smoker (currently nonsmoker)	85.6%	14.4%
Current smoker	92.0%	8.0
History of CVD (stroke, MI & congestive heart failure)
No	91.3%	8.7%
Yes	67.0%	33.0
Metabolic syndrome (meet at criteria for 3 or ATP III criteria)
No	88.2%	11.8%
Yes	88.2%	11.8
Renal dysfunction (eGFR in mL/min/1.73 m2 and proteinuria)
0–59	95.3%	33.7%
60–89 or eGFR ≥90 with proteinuria	89.8%	11.7%
≥90 with no proteinuria	61.9%	4.5
Renal dysfunction & metabolic syndrome
No metabolic syndrome and no renal dysfunction	96.3%	3.7%
No metabolic syndrome and early renal dysfunction	89.8%	10.2%
No metabolic syndrome and late renal dysfunction	61.9%	38.1%
Metabolic syndrome and no renal dysfunction	93.9%	6.1%
Metabolic syndrome and early renal dysfunction	86.4%	13.6%
Metabolic syndrome and late renal dysfunction	69.0%	31.0%